These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 17307126)

  • 1. Somatostatin-receptor-targeted alpha-emitting 213Bi is therapeutically more effective than beta(-)-emitting 177Lu in human pancreatic adenocarcinoma cells.
    Nayak TK; Norenberg JP; Anderson TL; Prossnitz ER; Stabin MG; Atcher RW
    Nucl Med Biol; 2007 Feb; 34(2):185-93. PubMed ID: 17307126
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A comparison of high- versus low-linear energy transfer somatostatin receptor targeted radionuclide therapy in vitro.
    Nayak T; Norenberg J; Anderson T; Atcher R
    Cancer Biother Radiopharm; 2005 Feb; 20(1):52-7. PubMed ID: 15778581
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 213Bi-[DOTA0, Tyr3]octreotide peptide receptor radionuclide therapy of pancreatic tumors in a preclinical animal model.
    Norenberg JP; Krenning BJ; Konings IR; Kusewitt DF; Nayak TK; Anderson TL; de Jong M; Garmestani K; Brechbiel MW; Kvols LK
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):897-903. PubMed ID: 16467104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha- versus beta-particle radiopeptide therapy in a human prostate cancer model (213Bi-DOTA-PESIN and 213Bi-AMBA versus 177Lu-DOTA-PESIN).
    Wild D; Frischknecht M; Zhang H; Morgenstern A; Bruchertseifer F; Boisclair J; Provencher-Bolliger A; Reubi JC; Maecke HR
    Cancer Res; 2011 Feb; 71(3):1009-18. PubMed ID: 21245097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancement of somatostatin-receptor-targeted (177)Lu-[DOTA(0)-Tyr(3)]-octreotide therapy by gemcitabine pretreatment-mediated receptor uptake, up-regulation and cell cycle modulation.
    Nayak TK; Atcher RW; Prossnitz ER; Norenberg JP
    Nucl Med Biol; 2008 Aug; 35(6):673-8. PubMed ID: 18678352
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro comparison of 213Bi- and 177Lu-radiation for peptide receptor radionuclide therapy.
    Chan HS; de Blois E; Morgenstern A; Bruchertseifer F; de Jong M; Breeman W; Konijnenberg M
    PLoS One; 2017; 12(7):e0181473. PubMed ID: 28732021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
    Boyd M; Ross SC; Dorrens J; Fullerton NE; Tan KW; Zalutsky MR; Mairs RJ
    J Nucl Med; 2006 Jun; 47(6):1007-15. PubMed ID: 16741311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors.
    Frilling A; Weber F; Saner F; Bockisch A; Hofmann M; Mueller-Brand J; Broelsch CE
    Surgery; 2006 Dec; 140(6):968-76; discussion 976-7. PubMed ID: 17188146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical evaluation of the alpha-particle generator nuclide 225Ac for somatostatin receptor radiotherapy of neuroendocrine tumors.
    Miederer M; Henriksen G; Alke A; Mossbrugger I; Quintanilla-Martinez L; Senekowitsch-Schmidtke R; Essler M
    Clin Cancer Res; 2008 Jun; 14(11):3555-61. PubMed ID: 18519789
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose rate dependence of the relative biological effectiveness of 103Pd for continuous low dose rate irradiation of BA1112 rhabdomyosarcoma cells in vitro relative to acute exposures.
    Nath R; Bongiorni P; Chen Z; Gragnano J; Rockwell S
    Int J Radiat Biol; 2005 Sep; 81(9):689-99. PubMed ID: 16368647
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.
    de Jong M; Breeman WA; Bernard BF; Bakker WH; Visser TJ; Kooij PP; van Gameren A; Krenning EP
    J Nucl Med; 2001 Dec; 42(12):1841-6. PubMed ID: 11752083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
    de Jong M; Breeman WA; Valkema R; Bernard BF; Krenning EP
    J Nucl Med; 2005 Jan; 46 Suppl 1():13S-7S. PubMed ID: 15653647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trifunctional somatostatin-based derivatives designed for targeted radiotherapy using auger electron emitters.
    Ginj M; Hinni K; Tschumi S; Schulz S; Maecke HR
    J Nucl Med; 2005 Dec; 46(12):2097-103. PubMed ID: 16330576
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes.
    Dadachova E; Howell RW; Bryan RA; Frenkel A; Nosanchuk JD; Casadevall A
    J Nucl Med; 2004 Feb; 45(2):313-20. PubMed ID: 14960655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radiosensitivity of Prostate Cancer Cell Lines for Irradiation from Beta Particle-emitting Radionuclide ¹⁷⁷Lu Compared to Alpha Particles and Gamma Rays.
    Elgqvist J; Timmermand OV; Larsson E; Strand SE
    Anticancer Res; 2016 Jan; 36(1):103-9. PubMed ID: 26722033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.
    Kratochwil C; Giesel FL; Bruchertseifer F; Mier W; Apostolidis C; Boll R; Murphy K; Haberkorn U; Morgenstern A
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2106-19. PubMed ID: 25070685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DNA double strand breaks as predictor of efficacy of the alpha-particle emitter Ac-225 and the electron emitter Lu-177 for somatostatin receptor targeted radiotherapy.
    Graf F; Fahrer J; Maus S; Morgenstern A; Bruchertseifer F; Venkatachalam S; Fottner C; Weber MM; Huelsenbeck J; Schreckenberger M; Kaina B; Miederer M
    PLoS One; 2014; 9(2):e88239. PubMed ID: 24516620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiproliferative effects of 111In- or 177Lu-DOTATOC on cells exposed to low multiplicity-of-infection double-deleted vaccinia virus encoding somatostatin subtype-2 receptor.
    Akinlolu O; Ottolino-Perry K; McCart JA; Reilly RM
    Cancer Biother Radiopharm; 2010 Jun; 25(3):325-33. PubMed ID: 20578838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of chemotherapeutic agents on expression of somatostatin receptors in pancreatic tumor cells.
    Fueger BJ; Hamilton G; Raderer M; Pangerl T; Traub T; Angelberger P; Baumgartner G; Dudczak R; Virgolini I
    J Nucl Med; 2001 Dec; 42(12):1856-62. PubMed ID: 11752085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiation-induced up-regulation of somatostatin receptor expression in small cell lung cancer in vitro.
    Oddstig J; Bernhardt P; Nilsson O; Ahlman H; Forssell-Aronsson E
    Nucl Med Biol; 2006 Oct; 33(7):841-6. PubMed ID: 17045163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.